| PMC full text: | Published online 2011 May 17. doi: 10.1186/1471-2474-12-99
|
Table 1
Baseline variables and major outcomes of patients in the study and across clusters
| Patients in the study n = 165 | Patients excluded n = 68 | Cluster 1, n = 43 | Cluster 2, n = 23 | Cluster 3, n = 72 | Cluster 4, n = 27 | |
|---|---|---|---|---|---|---|
| Age, mean, (range) * | 45 (21-69) | 42 (16-64) | 42 (21-62) | 46 (33-63) | 45 (24-69) | 49 (27-67) |
| Gender, % male | 54 | 50 | 56 | 46 | 49 | 70 |
| Pain, VAS mean, (SD)* | 4.4 (2.1) | 4.4 (2.4) | 3.7 (2.6) | 5.3 (1.9) | 4.6 (1.9) | 4.2 (2.1) |
| Leg pain, % | 48 | 48 | 35 | 47 | 53 | 57 |
| > 30 days of pain previous year, % * | 58 | 61 | 56 | 30 | 64 | 70 |
| EQ5D baseline, mean (range) | 0.73 (-0.05-1.00) | 0.78 (0.70-0.84) | 0.79 (-0.05-1.00) | 0.69 (0.26-0.84) | 0.72 (-0.05-1.00) | 0.70 (-0.05-0.84) |
| Improvement by 4th visit, % | 73 | 58 | 80 | 73 | 68 | 74 |
| Total number of days with bothersome pain, mean (SD) * | 38 (35) | 35 (32) | 33 (37) | 28 (20) | 35 (31) | 64 (39) |